Sign up to get free evidence-based articles, exclusive discounts, and insights from industry-leaders.
Email could not be subscribed.
Thank you for signing up!
presented by Nicole L. Stout, DPT, CLT-LANA, FAPTA
Financial — Nicole Stout is a Key Opinion Consultant: BSN Medical Consultant to the National Institutes of Health, Rehabilitation Medicine Department* Consultant to Survivorship Solutions LLC Nonfinancial — Chair, Oncology Specialty Council of the American Board of Physical Therapy Specialties
Satisfactory completion requirements: All disciplines must complete learning assessments to be awarded credit, no minimum score required unless otherwise specified within the course.
MedBridge is committed to accessibility for all of our subscribers. If you are in need of a disability-related accommodation, please contact [email protected]. We will process requests for reasonable accommodation and will provide reasonable accommodations where appropriate, in a prompt and efficient manner.
Nicole L. Stout, DPT, CLT-LANA, FAPTA
Dr. Nicole L. Stout is a research assistant professor in the School of Medicine, Department of Hematology/Oncology at West Virginia University Cancer Institute and with the School of Public Health, Department of Health Policy, Management, and Leadership. She also serves as the associate director of the WVU Cancer Institute's Survivorship Program, where she coordinates the…
Read full bioEmail could not be subscribed.
Thank you for signing up!
Thank you!
1. Classes of Hormonal Agents and Their Use in Cancer Treatment
In some types of cancers, cell growth can be accelerated by the presence of sex hormones. Hormone receptors are present on a majority of breast and prostate cancer cells. Adjuvant hormonal agents provide a mechanism to suppress tumor growth by reducing the impact of circulating hormones on the cancer cells.
2. Breast-Cancer-Related Hormonal Therapies: Side Effects and Clinical Management of Impairments
Specific drug classes are used to reduce the impact of estrogen and progesterone on breast cancer cell growth. These drugs, however, reduce the overall impact of hormones systemically and lead to metabolic and endocrine changes, joint arthralgias, weight gain, and loss of bone density. Rehabilitation interventions can minimize the severity of these side effects and their impact on function.
3. Prostate-Cancer-Related Hormonal Therapies: Side Effects and Clinical Management of Impairments
Specific drug classes are used to reduce the impact of androgen and testosterone on prostate cancer cell growth. These drugs, however, reduce the overall impact of hormones systemically and lead to metabolic and endocrine changes, reduced lean mass, and loss of bone density, and negatively impact libido. Rehabilitation interventions can minimize the severity of these side effects and their impact on function.
4. Considerations for Rehabilitation Interventions
The duration of hormonal therapy use is protracted, often over the course of several years, and side effects may be intermittent in onset or progressive over time. Consideration for screening and assessment of emerging impairment, mitigating the functional impact of these known side effects, and promoting evidence-based interventions can guide the rehabilitation plan of care and optimize function.
More Courses in this Series
Email could not be subscribed.
Thank you for signing up!
Email could not be subscribed.
Thank you for signing up!
For groups of 5 or more, request a demo to learn about our solution and pricing for your organization. For other questions or support, visit our contact page.